Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment.

@article{Strober2013EffectOT,
  title={Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment.},
  author={B E Strober and Marjorie Buonanno and J. Derrell Clark and Toshiki Kawabata and Huaming Tan and Robert A Wolk and Hernan Valdez and R G Langley and Jane A Harness and Alan Menter and K Papp},
  journal={The British journal of dermatology},
  year={2013},
  volume={169 5},
  pages={992-9}
}
BACKGROUND The Janus kinase (JAK) inhibitor, tofacitinib, has shown efficacy for the treatment of psoriasis in a phase IIb trial (A3921047; NCT00678210). OBJECTIVES To report haematology data from the phase IIb trial, given the importance of JAK-dependent signalling in haematopoiesis. METHODS Patients with moderate-to-severe chronic plaque psoriasis were randomized to receive tofacitinib 2, 5 or 15 mg, or placebo, twice daily over 12 weeks. Blood samples were collected at screening… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS